ClinicalTrials.gg
TerminatedNCT04222972AcceleRET-LungUpdated Mar 5, 2026Results posted

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of Pralsetinib and Carboplatin in RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm and Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Terminated at 74 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Enrollment
54th of 142
223 · median 136
Started
2020
with 9 others
Phase 3
48 of 182
2 open now
Registered
150th of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 54th largest by enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2020, is one of 48 in phase 3, and was the 150th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.

03

Conditions studied

  • RET-fusion Non Small Cell Lung Cancer
  • Lung Neoplasm
  • Carcinoma, Non-Small-Cell Lung
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Disease
  • Carcinoma, Bronchogenic
  • Bronchial Diseases
  • Head and Neck Neoplasms
  • Adenocarcinoma
  • Carcinoma
  • Neoplasms by Histologic Type
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Nerve Tissue

Keywords

  • Advanced Non-Small Cell Lung Cancer
  • RET Lung
  • RET Mutation
  • RET Alteration
  • RET Positive
  • RET Inhibitor
  • RET Altered
  • RET Rearrangement
  • RET NSCLC
  • RET-Rearranged NSCLC
  • RET Fusion
  • RET Fusion Lung Cancer
  • M918T
  • TRIM33-RET
  • Lung Cancer Mutation
  • BLU 667
  • Pralsetinib
  • RET Tyrosine Kinase
  • RET Gene Mutation
  • RET Kinase
  • Advanced Lung Cancer
  • Metastatic Lung Cancer
  • KIF5B-RET
  • CCDC6-RET
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's enrollment of 223 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed, definitively diagnosed, locally advanced (not able to be treated with surgery or radiotherapy) or NSCLC and has not been treated with systemic anticancer therapy for metastatic disease.
  • Participant must have a documented RET-fusion
  • Participant has based on 1.1 as determined by the local site Investigator/radiology assessment.
  • Participant has an Performance Status of 0 or 1.
  • Participant should not have received any prior anticancer therapy for metastatic disease.

    • Participants can have received previous anticancer therapy (except a selective RET inhibitor) in the or adjuvant setting but must have experienced an interval of at least ≥ 6 months from completion of therapy to recurrence.
    • Participants that received previous in the adjuvant or consolidation following chemoradiation are not allowed to receive pembrolizumab if randomized in Arm B
  • Participant is an appropriate candidate for and agrees to receive 1 of the Investigator choice platinum-based chemotherapy regimens if randomized to Arm B.
  • For women of : participants who agree to remain abstinent (refrain from heterosexual intercourse) or use .
  • For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom and agree to refrain from donating sperm.

Exclusion criteria

Exclusion criteria:

  • Participant's tumor has any additional known primary driver alterations other than RET, such as targetable mutations of EGFR, ALK, ROS1, MET, and BRAF. Investigators should discuss enrollment with Sponsor designee regarding co-mutations.
  • Participant previously received treatment with a selective RET inhibitor.
  • Participant received radiotherapy or radiosurgery to any site within 14 days before randomization or more than 30 Gy of radiotherapy to the lung in the 6 months before randomization.
  • Participant with a history of pneumonitis within the last 12 months.
  • Participant has or a primary CNS tumor that is associated with progressive neurological symptoms or requires increasing doses of to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for the 2 weeks before Cycle 1 Day 1.
  • Participant has had a history of another primary that has been diagnosed or required therapy within the past 3 years prior to randomization.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Pralsetinib

    Participants randomized to the Experimental Arm will receive Pralsetinib

    Drug: Pralsetinib

  • Active comparator
    Platinum-based chemotherapy with or without pembrolizumab

    Participants randomized to the Active Comparator Arm will receive 1 of 6 platinum-based chemotherapy treatment regimens (with or without pembrolizumab) at the study center as chosen by the treating Investigator (based on histology) Nonsquamous histology * Carboplatin or cisplatin / pemetrexed (with vitamin supplementation); with optional pemetrexed (with vitamin supplementation) maintenance. * Pembrolizumab / carboplatin or cisplatin / pemetrexed (with vitamin supplementation); followed by pembrolizumab and optional pemetrexed (with vitamin supplementation) maintenance. Squamous histology * Carboplatin or cisplatin / gemcitabine * Carboplatin with paclitaxel/nab-paclitaxel and pembrolizumab

    Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Pembrolizumab · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-Paclitaxel

Interventions

07

What researchers measure

Primary outcomes

  1. Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the date of first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (K-M) method was used to estimate median PFS. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 50 months

Secondary outcomes

  1. Arm A vs Arm B: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.

    Time frame: Up to approximately 50 months

  2. Arm A vs Arm B: Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: From randomization to death (up to approximately 50 months)

  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

    Time frame: Up to approximately 50 months

  4. Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

    ECOG is a 6-point scale (0-5) used to assess participants functional status, where, 0= Fully active, able to carry on all pre-disease performance without restriction; 1= restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2= ambulatory \& capable of all self-care but unable to carry out any work activities. Up \& about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5= dead.

    Time frame: Baseline up to 50 months

  5. Arm A vs Arm B: Duration of Response (DOR)

    DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate median DOR. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 50 months

  6. Arm A vs Arm B: Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants who experienced the best response of stable disease (SD) with a minimum duration of 6 months, a CR, or a PR, as assessed by investigator with use of RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.

    Time frame: Up to approximately 50 months

  7. Arm A vs Arm B: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who experienced the best response of CR, or PR, or SD, as assessed by investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.

    Time frame: Up to approximately 50 months

08

Results

Posted Mar 5, 2026

Participant flow

A total of 223 participants with rearranged during transfection (RET) fusion-positive metastatic non-small cell lung cancer (NSCLC) took part in the study at 74 investigative sites across 22 countries from 24 July 2020 to 27 January 2025. The study consists of a treatment period and a crossover period.

Treatment Period
Participant flow — Treatment Period
MilestoneArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
Started1131100
Safety-evaluable population1041080
Completed000
Not completed1131100
Withdrew: Adverse event310
Withdrew: Death26290
Withdrew: Informed consent withdrawn1980
Withdrew: Lost to follow-up130
Withdrew: Reason not specified960
Withdrew: Progressive disease3100
Withdrew: Study terminated by sponsor52530
Crossover Period
Participant flow — Crossover Period
MilestoneArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
Started0038
Completed000
Not completed0038
Withdrew: Adverse event002
Withdrew: Death008
Withdrew: Informed consent withdrawn002
Withdrew: Reason not specified003
Withdrew: Progressive disease002
Withdrew: Study terminated by sponsor0021

Outcome measures

PrimaryArm A vs Arm B: Treatment Period: Progression-free Survival (PFS)

PFS was defined as the time from randomization to the date of first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (K-M) method was used to estimate median PFS. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 50 months
Reported as:
Median · months
Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)
monthsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)9.0 (7.1 to 11.5)18.7 (11.1 to 25.2)
Statistical analysis
  • Arm A: Treatment Period- SOC vs Arm B: Treatment Period- Pralsetinib · Log Rank · p = 0.0027 · Hazard ratio (hr): 0.59 · 95% CI 0.42 to 0.84
SecondaryArm A vs Arm B: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.

Time frame:
Up to approximately 50 months
Reported as:
Number · percentage of participants
Arm A vs Arm B: Objective Response Rate (ORR)
percentage of participantsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Objective Response Rate (ORR)41.6 (32.40 to 51.24)65.5 (55.79 to 74.26)
Statistical analysis
  • Arm A: Treatment Period- SOC vs Arm B: Treatment Period- Pralsetinib · Cochran-Mantel-Haenszel · p = 0.0002 · Difference in overall response rates: 23.86 · 95% CI 10.25 to 37.47
SecondaryArm A vs Arm B: Overall Survival (OS)

OS was defined as the time from randomization to death from any cause. K-M method was used to estimate median OS. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
From randomization to death (up to approximately 50 months)
Reported as:
Median · months
Arm A vs Arm B: Overall Survival (OS)
monthsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Overall Survival (OS)39.8 (39.8 to NA)NA (29.6 to NA)
Statistical analysis
  • Arm A: Treatment Period- SOC vs Arm B: Treatment Period- Pralsetinib · Log Rank · p = 0.7423 · Hazard ratio (hr): 1.09 · 95% CI 0.65 to 1.85
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame:
Up to approximately 50 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
AEs10410838
SAEs386722
SecondaryNumber of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

ECOG is a 6-point scale (0-5) used to assess participants functional status, where, 0= Fully active, able to carry on all pre-disease performance without restriction; 1= restricted in physically strenuous activity but ambulatory \& able to carry out work of a light or sedentary nature, e.g., light housework, office work; 2= ambulatory \& capable of all self-care but unable to carry out any work activities. Up \& about more than 50% of waking hours; 3= capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4= completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5= dead.

Time frame:
Baseline up to 50 months
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
ParticipantsArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
Baseline ECOG Score 0: Post-baseline Score 014183
Baseline ECOG Score 0: Post-baseline Score 128227
Baseline ECOG Score 0: Post-baseline Score 2032
Baseline ECOG Score 0: Post-baseline Score 3011
Baseline ECOG Score 0: Post-baseline ECOG Missing001
Baseline ECOG Score 1: Post-baseline Score 0120
Baseline ECOG Score 1: Post-baseline ECOG 1464417
Baseline ECOG Score 1: Post-baseline ECOG 210114
Baseline ECOG Score 1: Post-baseline ECOG 3131
Baseline ECOG Score 1: Post-baseline ECOG 4021
Baseline ECOG Score 1: Post-baseline ECOG Missing420
Baseline ECOG Score 2: Post-baseline ECOG Missing001
SecondaryArm A vs Arm B: Duration of Response (DOR)

DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate median DOR. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 50 months
Reported as:
Median · months
Arm A vs Arm B: Duration of Response (DOR)
monthsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Duration of Response (DOR)9.7 (7.6 to 15.9)20.6 (17.2 to 31.8)
Statistical analysis
  • Arm A: Treatment Period- SOC vs Arm B: Treatment Period- Pralsetinib · Log Rank · p = 0.0043 · Hazard ratio (hr): 0.48 · 95% CI 0.28 to 0.80
SecondaryArm A vs Arm B: Clinical Benefit Rate (CBR)

CBR was defined as the percentage of participants who experienced the best response of stable disease (SD) with a minimum duration of 6 months, a CR, or a PR, as assessed by investigator with use of RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.

Time frame:
Up to approximately 50 months
Reported as:
Number · percentage of participants
Arm A vs Arm B: Clinical Benefit Rate (CBR)
percentage of participantsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Clinical Benefit Rate (CBR)58.4 (48.76 to 67.60)74.5 (65.35 to 82.37)
SecondaryArm A vs Arm B: Disease Control Rate (DCR)

DCR was defined as the percentage of participants who experienced the best response of CR, or PR, or SD, as assessed by investigator according to RECIST v1.1. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. CR was defined as the disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. 95% CI for rates were constructed using the Clopper-Pearson method. Percentages are rounded off.

Time frame:
Up to approximately 50 months
Reported as:
Number · percentage of participants
Arm A vs Arm B: Disease Control Rate (DCR)
percentage of participantsArm A: Treatment Period- SOCArm B: Treatment Period- Pralsetinib
Arm A vs Arm B: Disease Control Rate (DCR)79.6 (71.04 to 86.64)88.2 (80.64 to 93.55)

Adverse events

Collected over Up to approximately 50 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Treatment Period- SOC27/113 (23.9%)38/104 (36.5%)103/104 (99%)
Arm B: Treatment Period- Pralsetinib33/110 (30%)67/108 (62%)106/108 (98.1%)
Arm C: Crossover Period- Pralsetinib8/38 (21.1%)22/38 (57.9%)38/38 (100%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
PneumoniaInfections and infestations2/10416/1083/38
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1041/1084/38
PyrexiaGeneral disorders0/1047/1080/38
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1040/1082/38
PneumonitisRespiratory, thoracic and mediastinal disorders0/1045/1082/38
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1042/1082/38
Febrile neutropeniaBlood and lymphatic system disorders4/1041/1080/38
Pneumocystis jirovecii pneumoniaInfections and infestations0/1044/1080/38
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1044/1081/38
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/1042/1080/38
Most frequent other events
Showing 10 of 90
Most frequent other events
EventArm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibArm C: Crossover Period- Pralsetinib
AnaemiaBlood and lymphatic system disorders47/10452/10810/38
NauseaGastrointestinal disorders48/10420/1085/38
ConstipationGastrointestinal disorders30/10447/10812/38
Aspartate aminotransferase increasedInvestigations19/10445/1088/38
DiarrhoeaGastrointestinal disorders22/10444/1084/38
AstheniaGeneral disorders38/10427/1087/38
Alanine aminotransferase increasedInvestigations22/10439/1087/38
HypertensionVascular disorders4/10432/10812/38
CoughRespiratory, thoracic and mediastinal disorders13/10429/1088/38
NeutropeniaBlood and lymphatic system disorders19/10427/1087/38

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants whether or not the assigned study treatment is received.

Age, Continuous
Age, Continuous(years)Arm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibTotal
Mean62.3 ± 12.361.6 ± 11.161.9 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibTotal
Female6453117
Male4957106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibTotal
Hispanic or Latino191837
Not Hispanic or Latino7782159
Unknown or Not Reported171027
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Treatment Period- SOCArm B: Treatment Period- PralsetinibTotal
American Indian or Alaska Native7916
Asian222143
Black or African American224
White6568133
Other314
Unknown044
Not Reported14519
09

Study locations

74 sites
  • Hospital Britanico
    Buenos Aires, C1280AEB, Argentina
  • Centro Oncologico Riojano Integral (CORI)
    La Rioja, F5300COE, Argentina
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital A. C. Camargo
    São Paulo, São Paulo 01509-010, Brazil
  • Clinica CIMCA
    San José, 10103, Costa Rica
  • Institut Bergonie CLCC Bordeaux
    Bordeaux, 33000, France
  • Hôpital Ambroise Paré - Boulogne-Billancourt
    Boulogne-Billancourt, 92100, France
  • Hôpital Louis Pradel, Hospices Civils de Lyon
    Bron, 69677, France
  • CHRU Lille Service de Pneumologie et Oncologie Thoracique
    Lille, 59000, France
  • Institut Paoli Calmettes
    Marseille, 13273, France
  • Hopital Bichat Claude Bernard
    Paris, 75018, France
  • Hopital Tenon
    Paris, 75970, France
  • Hopital de Pontchaillou
    Rennes, 35033, France
  • Ico Rene Gauducheau
    Saint-Herblain, 44805, France
  • CHU Strasbourg - Nouvel Hopital Civil
    Strasbourg, 67091, France
  • CHU de Toulouse - Hôpital Larrey
    Toulouse, 31100, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Universitätsklinikum Carl Gustav Carus, Medizinische Klinik I, Pneumologie MK1-A13
    Dresden, 01307, Germany
  • Asklepios-Fachkliniken Muenchen-Gauting
    Gauting, 82131, Germany
  • Pius-Hospital
    Oldenburg, 26121, Germany
  • Leopoldina-Krankenhaus Medizinische Klinik II
    Schweinfurt, 97422, Germany
  • Klinik Schillerhöhe
    Stuttgart, 70376, Germany
  • St. James Hospital
    Dublin, D08 HNY1, Ireland
  • Ospedale Clinicizzato SS Annunziata
    Chieti, Abruzzo 66100, Italy
  • IRCCS Giovanni Paolo II Istituto Oncologico
    Bari, Apulia 70124, Italy
  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    Naples, Campania 80131, Italy
  • Ospedale Provinciale Santa Maria Delle Croci
    Ravenna, Emilia-Romagna 48100, Italy
  • Istituto Nazionale Tumori Regina Elena
    Rome, Lazio 00144, Italy
  • AZ. Ospedaliera San Giovanni - Addolorata
    Rome, Lazio 00184, Italy
  • Irccs Ospedale San Raffaele
    Milan, Lombardy 20132, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Lombardy 20133, Italy
  • Istituto Europeo Di Oncologia
    Milan, Lombardy 20141, Italy
  • Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello
    Pisa, Tuscany 56124, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS
    Padova, Veneto 35128, Italy
  • A.O.U. INTEGRATA DI VERONA-Ospedale Civile Maggiore Borgo Trento
    Verona, Veneto 37126, Italy
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • National Hospital Organization Himeji Medical Center
    Hyōgo, 670-8520, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • Kansai Medical University Hospital
    Osaka, 573-1191, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
  • The Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
  • National Hospital Organization Yamaguchi - Ube Medical Center
    Yamaguchi, 755-0241, Japan
  • Health Pharma Professional Research
    Mexico City, Mexico CITY (federal District) 03100, Mexico
  • NKI/AvL
    Amsterdam, 1066 CX, Netherlands
  • Maastricht University Medical Center
    Maastricht, 6229 HX, Netherlands
  • Oslo universitetssykehus HF, Ullevål, Kreftsenteret
    Oslo, 0450, Norway
  • Hemato Oncología de Panamá Especializada
    Panama City, 0801, Panama
  • Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
    Warsaw, 02-781, Poland
  • IPO do Porto
    Porto, 4200-072, Portugal
  • National Cancer Center
    Goyang-si, 10408, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Insititut Catala D'Oncologia
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, LA Coruna 15006, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal
    Madrid, 28050, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
  • Hosp Clinico Univ Lozano Blesa
    Zaragoza, 50009, Spain
  • Karolinska Universitetssjukhuset, Solna
    Stockholm, 171 76, Sweden
  • UniversitätsSpital Zürich
    Zurich, 8091, Switzerland
  • Adana City Hospital, Medical Oncology
    Adana, 01060, Turkey (Türkiye)
  • Ankara Bilkent City Hospital
    Ankara, 06490, Turkey (Türkiye)
  • ?zmir Medical Point
    Kar?iyaka, 35575, Turkey (Türkiye)
  • Velindre Cancer Centre
    Cardiff, CF14 2TL, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Guys & St Thomas Hospital
    London, SE1 9RT, United Kingdom
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • Christie Hospital Nhs Trust
    Manchester, M2O 4BX, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jan 2025, 54 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2020
First posted
Jan 10, 2020
StartActual
Jul 24, 2020
Primary completionActual
Jan 27, 2025
CompletionActual
Jan 27, 2025
Results first posted
Mar 5, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04222972
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 10, 2020
Start date
Jul 24, 2020
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Results posted
Mar 5, 2026
Last update
Mar 5, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralsetinib

Start the discussion